FDA OCE Message to Oncology Providers & Patients on COVID-19

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) issued a message on March 23 that outlines how critical issues for patients with cancer and their healthcare providers are continuing to be addressed despite the national COVID-19 health emergency. The message highlights the following as among the OCE's current priorities:

• Continuing to expedite oncology product development.
• Recognition that modifications may be required in clinical trials.
• Continuing Expanded Access requests for investigational products. Project Facilitate remains open at (240)402-0004 or ONCProjectFacilitate@fda.hhs.gov
  from 8:00 AM to 4:30 PM ET, M-F.
• Working to anticipate and prevent drug shortages.
• Keeping the cancer community informed.
  

Read message.

Posted 3/24/2020
Post updated 4/1/2020